PHG:NYE-Koninklijke Philips N.V. NY Registry Shares (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 26.96

Change

0.00 (0.00)%

Market Cap

USD 27.07B

Volume

1.29M

Analyst Target

USD 53.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Royal Philips NV is a diversified technology company which manufactures consumer electronics, appliances & equipments for healthcare, lighting and consumer well-being industry.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-14 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 187.15B
SYK Stryker Corporation

N/A

USD 129.94B
BSX Boston Scientific Corp

N/A

USD 111.10B
MDT Medtronic PLC

N/A

USD 106.70B
EW Edwards Lifesciences Corp

N/A

USD 52.36B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 23.69B
STE STERIS plc

N/A

USD 22.04B
SNN Smith & Nephew SNATS Inc

N/A

USD 11.07B
GMED Globus Medical

N/A

USD 8.83B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 8.19B

ETFs Containing PHG

CV9:PA Amundi Index Solutions - .. 2.68 % 0.00 %

N/A

USD 0.36B
BINV 2.31 % 0.00 %

N/A

N/A
INTF iShares Edge MSCI Multifa.. 0.00 % 0.30 %

N/A

USD 1.13B
HLTH:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.67B
ESIH:LSE iShares MSCI Europe Healt.. 0.00 % 0.00 %

N/A

USD 0.63B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.56% 79% B- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.56% 79% B- 86% B+
Trailing 12 Months  
Capital Gain 30.68% 77% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.68% 77% C+ 77% C+
Trailing 5 Years  
Capital Gain -34.34% 25% F 15% F
Dividend Return 7.14% 63% D 23% F
Total Return -27.20% 25% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -9.17% 23% F 10% F
Dividend Return -7.54% 29% F 9% A-
Total Return 1.63% 63% D 39% F
Risk Return Profile  
Volatility (Standard Deviation) 35.54% 55% F 30% F
Risk Adjusted Return -21.20% 26% F 15% F
Market Capitalization 27.07B 82% B 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.60 35% 7%
Price/Book Ratio 1.41 78% 56%
Price / Cash Flow Ratio 11.34 56% 34%
Price/Free Cash Flow Ratio 23.77 21% 10%
Management Effectiveness  
Return on Equity -3.58% 45% 22%
Return on Invested Capital -0.21% 47% 24%
Return on Assets 0.87% 48% 31%
Debt to Equity Ratio 50.67% 43% 61%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector